Health Care Biotech and Pharmaceuticals

More

  • Bill Ackman

    After Valeant took a bite out of Bill Ackman's hedge fund, the billionaire described his firm's standing to CNBC's Scott Wapner.

  • Sir Andrew Witty, CEO, GlaxoSmithKline.

    GlaxoSmithKline said its CEO Andrew Witty would retire in 12 months, prompting Britain's biggest drugmaker to start a formal search for his successor.

  • The headquarters of Valeant Pharmaceuticals International in Laval, Quebec.

    Creditors of Valeant Pharmaceuticals are beginning to demand new terms that could further pressure the drugmaker's business model, sources said.

  • Don't invest in biotech for safety: JP Morgan strategist

    Michael Bell, global market strategist at JP Morgan, discusses investing in pharma and biotech.

  • Cancer research pt.2

    Access, diagnostics and the quality of cancer care are challenges in developing countries, warns Dr Masum Hossain, APAC regional president and managing director of Pfizer Oncology.

  • Cancer research

    Dr Masum Hossain, APAC regional president and managing director of Pfizer Oncology, explains why immunotherapy is a priority for the pharmaceutical firm, especially in Asia.

  • Jim Grant

    Longtime Fed and Valeant bear Jim Grant joined CNBC to discuss the pharma stock and the Fed's move on Wednesday.

  • Bill Ackman

    The drug company's stock closed down 51% to $33.54 a share Tuesday on disappointing financial news, USA TODAY reports.

  • Valeant under pressure

    David Maris, Wells Fargo Securities, and CNBC's Meg Tirrell talk about Valeant Pharm's future.

  • Valeant fallout puts hedge funds in crosshairs

    CNBC's Meg Tirrell reports Valeant's stunning fall has left some smaller hedge funds vulnerable, and an number of investors feeling as though they have to ride it out and see what happens.

  • Valeant shares fall 50% on default risk

    CNBC's Meg Tirrell reports on Valeant's wild ride as the stock plummeted and Moody's downgrades the company's debt. Also a look at which hedge funds lost billions of dollars in the rout.

  • Valeant Default risk

    Steve Brozak, managing partner and president at WBB Securities, said it's important to see if Valeant's business model can support its level of debt.

  • Mark Trudeau, chief executive officer of Mallinckrodt Plc

    Andrew Left of Citron Research explains why Mallinckrodt is worse than Valeant. Mark Trudeau, Mallinckrodt CEO, responds.

  • Bill Ackman at the New York Stock Exchange.

    Wall Street investor Bill Ackman says he is still confident in Valeant and he plans to be more proactive in his dealings with it.

  • GW Pharma CEO: Our most important clinical event

    GW Pharmaceuticals' CEO Justin Gover says this successful clinical trial for new drug Epidiolex is not only good for the company but also for cannabinoids in modern medicine. CNBC's Meg Tirrell reports.

  • GW Pharma has investors on a high

    GW Pharma's phase 3 study on its cannabinoid Epidiolex shows positive results for epilepsy, sending shares of the company higher, reports CNBC's Meg Tirrell.

  • GW Pharmaceuticals cannabis laboratory

    "This is a way to get rid of a terrible, terrible drug, oxycodone," CNBC's Jim Cramer says.

  • Politics of big pharma

    CNBC's Meg Tirrell takes a look at where the presidential candidates stand on big pharma issues.

  • Kyle Bass challenges Acorda patents

    Kyle Bass, who started the Coalition for Affordable Drugs, has challenged a drug patent from biotech company Acorda, reports CNBC's Meg Tirrell.

  • Investing in immunotherapy

    Loncar Investments CEO, Brad Loncar says immunotherapy is the most innovative, high-growth area in the biotech space, while describing the company’s ETF.

Contact Biotech and Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about about our products and service. Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.